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Introduction {#sec1}
============

A major driver of metabolic reprogramming in cancer is the c-Myc proto-oncogene (Myc), a transcription factor that broadly regulates the expression of genes involved in anabolic metabolism and cellular bioenergetics.[@bib1] Oncogene activation or tumor suppressor inactivation promotes changes in cellular metabolism that facilitate transformation and tumor cell proliferation.[@bib2] However, the increased metabolic activity stimulated by transformation imposes additional stresses on tumor cells, such as nutrient depletion and redox imbalance, which must be countered for tumors to survive and grow. The liver kinase B1 (LKB1)-AMP-activated protein kinase (AMPK) pathway contributes to tumor cell survival by promoting the cellular sensing of and adaptation to such bioenergetic stress.[@bib3] Inactivation of LKB1 in cancer, conversely, promotes anabolic metabolic reprogramming at the expense of metabolic flexibility.[@bib4], [@bib5], [@bib6], [@bib7] In cells lacking LKB1, including non-small cell lung cancer (NSCLC), AMPK activation is reduced and cells are more sensitive to metabolic stresses induced by nutrient limitation or inhibitors of oxidative phosphorylation (OXPHOS).[@bib8]^,^[@bib9] This raises the possibility of using OXPHOS inhibitors to target cancers with reduced bioenergetic capacity and/or defects in energy-sensing control systems. Potent OXPHOS inhibitors,[@bib10] putative inhibitors of mitochondrial protein synthesis,[@bib11]^,^[@bib12] and enhancers of the degradation of respiratory chain proteins[@bib13]^,^[@bib14] are under study as antineoplastic agents.

Biguanides represent another class of drugs proposed to target cellular bioenergetics in tumor cells. The most well-known biguanide is metformin, a drug commonly used to treat type 2 diabetes. Metformin reduces the activity of mitochondrial complex I, thereby limiting mitochondrial ATP production and imposing bioenergetic stress on cells.[@bib15]^,^[@bib16] This leads to reduced hepatic gluconeogenesis and reduced hyperglycemia in type 2 diabetes. However, if adequate drug levels can be achieved in other cell types, lineage-specific consequences of energetic stress are observed, including cytostatic or cytotoxic effects on cancer cells.[@bib17] Older retrospective studies[@bib18] reported that diabetics treated with metformin had reduced cancer risk and better cancer prognosis relative to diabetic patients not taking metformin,[@bib18] generating interest in repurposing biguanides as anticancer agents.[@bib17] However, further pharmaco-epidemiologic studies[@bib19]^,^[@bib20] failed to confirm these findings, and early randomized clinical trials of metformin in advanced cancer have shown no survival benefit in pancreatic cancer[@bib21] and only minor benefit in lung cancer.[@bib22] Pharmacokinetic factors, such as the requirement for the active transport of metformin by the organic cation 1 (OCT1) transporters, may account in part for the discrepancies between preclinical models and clinical trials with respect to the anticancer effects of metformin. Nevertheless, many *in vivo* cancer models demonstrate significant *in vivo* antineoplastic activity of biguanides,[@bib6]^,^[@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29] raising the possibility that biguanides with better bioavailability and toxicity profiles may have clinical utility.

Important in the clinical development of OXPHOS inhibitors as antineoplastic drugs is the selection of subsets of cancers that are particularly sensitive to metabolic stress. Preclinical work by Shackelford et al.[@bib8] demonstrated that biguanides, specifically phenformin, could be effective as single agents for LKB1-deficient KRAS mutant NSCLC, in keeping with the role of LKB1 in adaptation to energetic stress. While the mutation of LKB1 is found in ∼20%--30% of NSCLCs, we hypothesized that biguanide-sensitive cancers can be extended to those with increased expression of MYC, which we have previously reported promotes translational suppression of LKB1 via the microRNA (miRNA) *miR-17∼92*.[@bib30] In this study, using loss- and gain-of-function models of *miR-17∼92*, we demonstrate that elevated *miR-17∼92* expression, specifically the seed family *miR-17 and* -*20*, confers increased sensitivity of mouse and human lymphoma cells to apoptosis induced by two biguanides---phenformin and the newly developed biguanide IM156. As single agents, both phenformin and IM156, but not metformin, extended the survival of mice bearing *miR-17∼92*-expressing lymphomas. These results suggest that *miR-17∼92* could function as a biomarker for biguanide sensitivity in cancer.

Results {#sec2}
=======

IM156 Is a Newly Developed Biguanide That Inhibits Mitochondrial Respiration {#sec2.1}
----------------------------------------------------------------------------

The limited bioavailability of metformin and its dependence on OCT1 for cellular uptake potentially limit its applicability in the treatment of cancer.[@bib31] We investigated the biological properties of phenformin and the newly developed biguanide IM156, which are more hydrophobic and therefore potentially more bioavailable to cells than metformin ([Figure 1](#fig1){ref-type="fig"}A). To test the impact of these biguanides on tumor cell respiration, we acutely treated *Myc*-dependent mouse lymphoma cells (*Eμ-Myc* cells) with either metformin, phenformin, or IM156 and assessed changes in the oxygen consumption rate (OCR) using the Seahorse XF96 extracellular flux analyzer. Across a range of concentrations, phenformin and IM156 decreased OCR ([Figure 1](#fig1){ref-type="fig"}B), with IM156 exhibiting greater potency than phenformin and metformin at equal concentrations. IM156 was more effective than phenformin at reducing cellular ATP production at equal concentrations, correlating with the effect of IM156 on oxidative phosphorylation ([Figure 1](#fig1){ref-type="fig"}C). These data are consistent with IM156 functioning as a more potent inhibitor of mitochondrial respiration than phenformin.Figure 1IM156 Is a Newly Developed Biguanide That Inhibits Mitochondrial Respiration(A) Chemical structure of the biguanides metformin, phenformin, and IM156.(B) Dose-dependent reduction of the OCR of Eμ-*Myc*^+^ lymphoma cells by metformin, phenformin, and IM156. Data were derived from the maximal point of OCR reduction after 30 min of treatment with the indicated biguanide and expressed relative to untreated cells at the same time point. Data represent mean ± SEM for biological replicates (n = 4--6 per drug per concentration).(C) Mitochondrial ATP production rate of Eμ-*Myc*^+^ lymphoma cells after incubation with 100 μM of either vehicle, phenformin (Phen), or IM156. Data represent mean ± SD for biological replicates (n = 8--9 per group).(D) Dose-dependent inhibition of substrate oxidation by electron transport chain complexes in IM156-treated purified bovine mitochondrial membranes. NADH oxidation was measured for complex I, III, and IV activity (dark blue), and succinate oxidation was measured for complex II, III, and IV activity (gray) over the indicated concentrations of IM156. Data represent mean ± SD for technical replicates (n = 3--4 per group). See also [Figure S1](#mmc1){ref-type="supplementary-material"}A.(E) Dose-dependent reduction of OCR by IM156 in HEK293T cells expressing empty vector (Ctrl) or yeast NDI1 (NDI1). Data were derived from the maximal point of OCR reduction after 30 min of treatment with IM156 and expressed relative to the maximal OCR at the same time point and group. Data represent mean ± SD for technical replicates (n = 10 per concentration per group).(F) Immunoblot for phosphorylated (pAMPK, T172) and total AMPKα following treatment with vehicle or equivalent doses of phenformin (100 μM) or IM156 (10 μM) for 2 h. Actin is shown as a loading control.(G) Viability of Eμ-*Myc*^+^ lymphoma cells following 48 h treatment with phenformin or IM156, comparing 10 different doses. EC~50~ for each treatment is indicated. Data represent mean ± SEM for biological replicates (n = 3 per drug per concentration).∗p \< 0.05, ∗∗p \< 0.01, and ∗∗∗p \< 0.001.

To confirm that the effect of IM156 on mitochondrial respiration was through complex I inhibition, we treated purified bovine mitochondrial membranes with IM156. IM156 treatment decreased complex I-dependent NADH oxidation in a significant, dose-dependent manner, with a lower half-maximal inhibitory concentration (IC~50~) (2.2 μM) than previously reported for phenformin (340 μM),[@bib16] while succinate oxidation (via complex II) was minimally affected at equivalent doses of IM156 ([Figure 1](#fig1){ref-type="fig"}D). This minimal decrease in succinate oxidation could be an effect of IM156 on any of the complexes II, III, or IV, but could also be an effect of the drug on the coupled assay enzymes fumarase and malic enzyme. IM156 also reduced NADH oxidation in purified complex I in a dose-dependent manner ([Figure S1](#mmc1){ref-type="supplementary-material"}A). To further confirm the specificity of IM156 for complex I, we assessed the IM156-mediated inhibition of OCR in cells expressing NDI1, a yeast NADH dehydrogenase that is resistant to biguanides.[@bib28] NDI1 expression rescued the effects of IM156 on cellular respiration, promoting an ∼100-fold shift in the IC~50~ of IM156 ([Figure 1](#fig1){ref-type="fig"}E). These data support that IM156 blocks OXPHOS through the inhibition of complex I and does so more potently than phenformin.

We next determined whether phenformin and IM156 similarly activate the energy sensor AMPK, as depletion of cellular ATP by biguanide treatment is a known trigger for AMPK activation.[@bib7] Given the difference in potency of phenformin and IM156, we used doses (100 and 10 μM, respectively) that produced an equivalent ∼50% decrease in OCR from baseline after a 2-h treatment ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). A 2-h treatment with these concentrations of phenformin or IM156 yielded similar levels of activating AMPK phosphorylation at T-172 ([Figure 1](#fig1){ref-type="fig"}F). Lastly, we treated *Eμ-Myc*^*+*^ lymphoma cells with a range of concentrations of either phenformin or IM156. Based on cell viability measurements, IM156 exhibited higher potency and induced lymphoma cell death at lower concentrations than phenformin (half-maximal effective concentration \[EC~50~\] of 12 μM for IM156 compared to 62 μM for phenformin; [Figure 1](#fig1){ref-type="fig"}G).

*miR-17∼92* Sensitizes Lymphoma Cells to Apoptosis by Biguanides {#sec2.2}
----------------------------------------------------------------

Previously, we demonstrated that the oncogenic miRNA cluster *miR-17∼92* is required for *Myc*-dependent metabolic reprogramming in lymphoma and does so in part through the translational suppression of LKB1.[@bib30] We examined whether the expression of *miR-17∼92* alters the sensitivity of lymphoma cells to biguanide treatment. We used Eμ-*Myc* B cell lymphoma cells harboring floxed *miR-17∼92* alleles, which allowed us to study the effect of the conditional deletion of *miR-17∼92* in the presence of constitutive *Myc* expression.[@bib32] Eμ-*Myc* lymphoma cells deleted for *miR-17∼92* (Δ/Δ) were more resistant to phenformin treatment than their isogenic counterparts expressing *miR-17∼92* (*fl/fl*) ([Figure 2](#fig2){ref-type="fig"}A). Phenformin treatment actively induced apoptosis in *miR-17∼92*-expressing Eμ-*Myc* lymphoma cells as shown by the presence of active (cleaved) caspase-3 ([Figure 2](#fig2){ref-type="fig"}B). Levels of caspase-3 cleavage were markedly reduced in Eμ-*Myc* lymphoma cells lacking *miR-17∼92* ([Figure 2](#fig2){ref-type="fig"}B).Figure 2*miR-17∼92* Sensitizes Lymphoma Cells to Apoptosis by Biguanides(A) Viability of Ctrl (fl/fl) and *miR-17∼92*-deficient (Δ/Δ) Eμ-*Myc*^+^ lymphoma cells untreated (Ctrl, gray) or treated with 100 μM phenformin (Phen, blue) for 48 h. Data represent mean ± SD for biological replicates (n = 3 per group).(B) Immunoblot for active (cleaved) caspase-3 in cells treated as in (A). Actin is shown as a loading control.(C) Dose of phenformin (left) or IM156 (right) required to achieve 50% decrease in cell viability (EC~50~) in biguanide-sensitive Eμ-*Myc*^+^ lymphoma cells expressing control (Ctrl) or *miR-17∼92* (+17∼92) expression vectors. Cell viability was measured 48 h post-biguanide treatment. See also [Figures S1](#mmc1){ref-type="supplementary-material"}B and [S1](#mmc1){ref-type="supplementary-material"}C.(D) Viability of control (Ctrl) or *miR-17∼92*-expressing (+17∼92) Raji cells after 48 h treatment with 100 μM phenformin. Histogram shows representative staining for cell death using fluorescent viability dye (FVD), which is quantified at right. Data represent mean ± SD for biological replicates (n = 3 per group).(E) Dose of phenformin (left) or IM156 (right) required to achieve a 50% decrease in cell viability (EC~50~) in biguanide-resistant Raji cells expressing control (Ctrl) or *miR-17∼92* (+17∼92) expression vectors following 48 h of treatment with biguanide.∗p \< 0.05, ∗∗p \< 0.01, and ∗∗∗p \< 0.001.

Since *miR-17∼92* is recurrently amplified in lymphoma,[@bib33]^,^[@bib34] we next tested whether an increased copy number of *miR-17∼92* was sufficient to increase the sensitivity of lymphoma cells to biguanides. To test this, we generated Eμ-*Myc* lymphoma cells and Raji lymphoma cells, a human Burkitt's lymphoma cell line known to display low MYC levels,[@bib30] with ectopic expression of the entire *miR-17∼92* polycistron (hereafter denoted as *+17∼92*). Eμ-*Myc* lymphoma cells overexpressing *miR-17∼92* were significantly more sensitive than control cells when treated with either phenformin or IM156 ([Figures 2](#fig2){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}B). *miR-17∼92* overexpression led to a 10-fold shift in the EC~50~ of Eμ-*Myc* cells to IM156 treatment (2 μM versus 24 μM). Similar results were observed in Raji cells engineered to express higher levels of *miR-17∼92* ([Figures 2](#fig2){ref-type="fig"}D, 2E, and [S1](#mmc1){ref-type="supplementary-material"}C). Although Raji cells were less sensitive to biguanide treatment, with EC~50~ values ranging from 90 μM to 3.5 mM as compared to Eμ*-Myc*^*+*^ EC~50~ values ranging from 2 to 62 μM ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C), the overexpression of *miR-17∼92* still conferred a ∼3-fold increase in sensitivity to biguanides compared to control cells. These data indicate that elevated *miR-17∼92* enhances the sensitivity of lymphoma cells to biguanide treatments and that *Myc* and *miR-17∼92* synergize to increase sensitivity to biguanide treatment.

We next asked whether the enhanced sensitivity to biguanides observed *in vitro* extended to *in vivo* models. Nude mice harboring either control or *miR-17∼92*-overexpressing Eμ-*Myc* cells were administered phenformin or IM156 in their drinking water *ad libitum*, and survival was tracked compared to tumor-bearing mice administered regular drinking water. While biguanide treatment of mice bearing control lymphoma cells produced no discernible survival benefit ([Figure 3](#fig3){ref-type="fig"}A), both phenformin and IM156 significantly prolonged the lifespan of mice bearing aggressive *miR-17∼92*-overexpressing tumors ([Figure 3](#fig3){ref-type="fig"}B). Our observations indicate that phenformin and IM156 can act as single agents to extend the survival of mice bearing tumors with elevated *miR-17∼92* expression, with elevated *miR-17∼92* expression functioning as a predictor of sensitivity to biguanides.Figure 3Biguanide Treatment Selectively Impairs the Growth of *miR-17∼92*-Expressing Lymphoma Cells *In Vivo*(A and B) Kaplan-Meier curves for the viability of nude mice injected with 1 × 10^6^*Myc*^*+*^/Ctrl (A) or *Myc*^*+*^/+17∼92 (B) lymphoma cells. Mice were provided with untreated water (Ctrl, n = 10), 0.9 mg/mL phenformin (Phen, n = 8), or 0.8 mg/mL IM156 (IM156, n = 10) *ad libitum* following intravenous tumor cell injection.∗p \< 0.05, ∗∗p \< 0.01, and ∗∗∗p \< 0.001.

*miR-17∼92* Confers Sensitivity to Biguanides through the Suppression of LKB1 {#sec2.3}
-----------------------------------------------------------------------------

We next explored the mechanism by which elevated *miR-17∼92* expression confers biguanide sensitivity in lymphoma cells. NSCLC cells that have lost LKB1 display increased sensitivity to phenformin.[@bib8] We previously identified LKB1 as a target of gene silencing by *miR-17∼92* via *miR-17*- and -*20*-dependent suppression of LKB1 protein expression.[@bib30] Deletion of *miR-17∼92* in Eμ*-Myc* cells (Δ/Δ cells) increased LKB1 protein levels ([Figure 4](#fig4){ref-type="fig"}A), while over-expression of *miR-17∼92* reduced LKB1 levels ([Figure 4](#fig4){ref-type="fig"}B). Increased *miR-17∼92* expression resulted in reduced AMPK phosphorylation ([Figure 4](#fig4){ref-type="fig"}B), which downregulated Ser-792 phosphorylation of Raptor ([Figure 4](#fig4){ref-type="fig"}C) and thus enhanced mammalian target of rapamycin complex 1 (mTORC1) signaling, as evidenced by the increased phosphorylation of rS6 and 4EBP phosphorylation in *miR-17∼92-*expressing cells ([Figure 4](#fig4){ref-type="fig"}C). The deletion of *miR-17∼92* in Eμ*-Myc* cells (Δ/Δ cells) was sufficient to confer a survival advantage in response to IM156 treatment ([Figure 4](#fig4){ref-type="fig"}D). Reducing LKB1 expression in Δ/Δ cells using small hairpin RNAs (shRNAs) targeting LKB1[@bib30] restored biguanide sensitivity in Δ/Δ cells to match that observed in lymphoma cells expressing *miR-17∼92* ([Figure 4](#fig4){ref-type="fig"}D). Similarly, lymphoma cells expressing *miR-17∼92* but lacking expression of *miR-17* and *-20* were resistant to IM156 treatment ([Figure 4](#fig4){ref-type="fig"}E).Figure 4*miR-17∼92* Confers Sensitivity to Biguanides through the Suppression of LKB1(A) Immunoblot of LKB1 and actin protein levels in Ctrl (fl/fl) and miR-17∼92-deficient (Δ/Δ) Eμ-*Myc*^+^ lymphoma cells.(B and C) Immunoblot of AMPK pathway (B) and mTORC1 pathway (C) activation in control (Ctrl) or miR-17∼92-expressing (+17∼92) Eμ-*Myc*^+^ lymphoma cells. AMPK activation was determined by measuring total and phosphorylated (p-AMPK, T172) AMPKα. mTORC1 activity was assessed by measuring levels of total and phosphorylated ribosomal S6 protein (rS6, S235/236), 4EBP (T37/46), and Raptor (S792).(D) Viability of the following Eμ-*Myc*^+^ lymphoma cells: Ctrl (fl/fl), miR-17∼92-deficient (Δ/Δ), and miR-17∼92-deficient expressing shRNAs targeting LKB1 (Δ/Δ+shLKB1/2). Cells were treated with 10 μM IM156 for 48 h and viability assessed by flow cytometry. Data represent mean ± SD for biological replicates (n = 3 per group).(E) Viability of Eμ-*Myc*^+^ lymphoma cells expressing *miR-17∼92* (+17∼92) or *miR-17∼92* lacking the miR-17 and -20 seed families (+17∼92Δ(17+20)). Cells were treated with vehicle (Ctrl) or 10 μM IM156 for 48 h and viability assessed by flow cytometry. Data represent mean ± SD for biological replicates (n = 3 per group).(F) Immunoblot of total and phosphorylated (p-AMPK, T172) AMPKα levels in control (Ctrl) and *miR-17∼92*-expressing (+17∼92) Eμ-*Myc*^+^ lymphoma cells following a 2-h treatment with vehicle (--), 100 μM phenformin (+Phen), or 10 μM IM156 (+IM156).(G) Schematic of transcriptional differences in miRNA between control (fl/fl) and *miR-17∼92* expressing Eμ-*Myc*^+^ lymphoma cells. miR-17 and -20 are responsible for the repression of LKB1, which increases biguanide sensitivity.∗p \< 0.05, ∗∗p \< 0.01, and ∗∗∗p \< 0.001.

Given that an increased copy number of *miR-17∼92* leads to LKB1 repression in lymphoma cells ([Figure 4](#fig4){ref-type="fig"}B), we tested whether AMPK activation was differentially engaged downstream of either phenformin or IM156 treatment. Lymphoma cells overexpressing *miR-17∼92* displayed reduced AMPK phosphorylation following phenformin or IM156 treatment compared to control cells ([Figure 4](#fig4){ref-type="fig"}F), suggesting uncoupling of the LKB1-AMPK axis to metabolic stress ([Figure 4](#fig4){ref-type="fig"}G).

Biguanide Treatment Affects Central Carbon Metabolism in *miR-17∼92*-Expressing Myc^+^ Lymphoma Cells {#sec2.4}
-----------------------------------------------------------------------------------------------------

We next characterized the effect of IM156 treatment on lymphoma cell bioenergetics using a Seahorse XF96 extracellular flux analyzer. Lymphoma cells overexpressing *miR-17∼92* exhibit higher basal metabolic rates, both in terms of glycolytic rate (extracellular acidification rate \[ECAR\]) and respiration (OCR), than control cells ([Figure 5](#fig5){ref-type="fig"}A). This corresponded to higher overall rates of ATP production by *miR-17∼92*-expressing lymphoma cells compared to controls, which was due largely to increased glycolytic ATP production ([Figure 5](#fig5){ref-type="fig"}B). *miR-17∼92*-expressing lymphoma cells also displayed a larger bioenergetic scope than control cells ([Figure 5](#fig5){ref-type="fig"}C). The bioenergetic profile of both cell types was significantly altered by IM156 treatment, characterized by a decrease in mitochondrial ATP production (*J*~*ATP*~ *ox*) and an increase in glycolytic ATP production (*J*~*ATP*~ *gly*) ([Figure 5](#fig5){ref-type="fig"}C). IM156 reduced OXPHOS-derived ATP production in both cell types by \>50% ([Figure 5](#fig5){ref-type="fig"}C).Figure 5Biguanide Treatment Affects Central Carbon Metabolism in *miR-17∼92*-Expressing Lymphoma Cells(A) ECAR and OCR of control (Ctrl) or *miR-17∼92*-expressing (+17∼92) Eμ-*Myc*^+^ lymphoma cells. Data represent mean± SD for biological replicates (n = 12 per group).(B) ATP production rates (J~ATP~) for Eμ-*Myc*^+^ lymphoma cells expressing control (Ctrl) or miR-17∼92 (+17∼92) expression vectors. Seahorse experiments were performed under standard cell culture media conditions (Glc, 25 mM; Gln, 2 mM). J~ATP~total is the sum of the glycolytic (J~ATP~gly) and OXPHOS (J~ATP~ox) ATP production rates. Data represent mean ± SDs for biological replicates (n = 12 per group) (Ctrl, n = 8; Ctrl+IM156, n = 8; +17∼92, n = 11; +17∼92+IM156, n = 12).(C) Bioenergetic capacity plot of Eμ-*Myc*^+^ lymphoma cells expressing control (Ctrl) or miR-17∼92 overexpression (+17∼92) vectors following a 2-h treatment with vehicle (gray) or IM156 (purple). Rectangles define the maximum bioenergetic space of each cell type.(D) Heatmap showing relative metabolite abundances for control (Ctrl) or *miR-17∼92*-expressing (+17∼92) Eμ-*Myc*^+^ lymphoma cells following a 2-h treatment with vehicle (Ctrl), phenformin (Phen), or IM156 (n = 3 per group).(E) Fractional enrichment of U-\[^13^C\]-glucose-derived lactate in *miR-17∼92*-expressing Eμ-*Myc*^+^ lymphoma cells following a 2-h treatment with vehicle (Ctrl), phenformin (Phen), or IM156. Data represent mean ± SD for biological replicates (n = 3 per group).(F) Fractional enrichment of U-\[^13^C\]-labeled glutamine in *miR-17∼92*-expressing Eμ-*Myc*^+^ lymphoma cells following a 2-h treatment with vehicle (Ctrl), phenformin (Phen), or IM156. Data represent mean ± SD for biological replicates (n = 3 per group).(G) Fractional enrichment of U-\[^13^C\]-glucose-derived citrate and U-\[^13^C\]-glutamine-derived citrate and aspartate in *miR-17∼92*-expressing Eμ-*Myc*^+^ lymphoma cells, following a 2-h treatment with vehicle (Ctrl), phenformin (Phen), or IM156. Data represent mean ± SD for biological replicates (n = 3 per group).∗p \< 0.05, ∗∗p \< 0.01, and ∗∗∗p \< 0.001.

We next examined the impact of biguanide treatment on metabolite dynamics in lymphoma cells. Consistent with their increased bioenergetic profile ([Figures 5](#fig5){ref-type="fig"}A--5C), *miR-17∼92*-expressing lymphoma cells displayed an increased abundance of metabolites involved in glycolysis (e.g., pyruvate, lactate), the tricarboxylic acid (TCA) cycle (e.g., citrate, succinate, fumarate, malate), and amino acid metabolism ([Figure 5](#fig5){ref-type="fig"}D). Biguanide treatment had a minimal effect on amino acid levels in either cell type ([Figure 5](#fig5){ref-type="fig"}D). However, levels of TCA cycle intermediates were markedly reduced in *miR-17∼92*-expressing cells upon treatment with phenformin or IM156 ([Figure 5](#fig5){ref-type="fig"}D). This may be the result of the stalled processing of TCA cycle intermediates due to NADH buildup following complex I inhibition, as previously suggested.[@bib35] This was not due to an inhibition of glucose or glutamine uptake, as ^13^C-tracing experiments revealed no change in glucose trafficking to lactate ([Figure 5](#fig5){ref-type="fig"}E) or glutamine uptake ([Figure 5](#fig5){ref-type="fig"}F) in the presence of phenformin or IM156, consistent with previous findings using phenformin.[@bib36] The lack of increased intracellular ^13^C-glucose-derived lactate in phenformin- or IM156-treated cells may be due to increased export into the culture medium, as suggested by the shift in glycolytic ATP production in IM156-treated cells ([Figure 5](#fig5){ref-type="fig"}C). Biguanide treatment blunted ^13^C-glucose and ^13^C-glutamine entry into the TCA cycle, as evidenced by the reduced conversion of glucose and glutamine to citrate ([Figure 5](#fig5){ref-type="fig"}G). ^13^C-glutamine-derived production of aspartate, a key intermediate for protein and nucleotide biosynthesis and tumor cell growth,[@bib35]^,^[@bib36] was reduced by 60%--65% following a 2-h administration of phenformin or IM156 ([Figure 5](#fig5){ref-type="fig"}H). These data suggest that although *miR-17∼92* enhances central carbon metabolism and bioenergetic potential in lymphoma cells, these pathways are uniquely sensitive to biguanide treatment.

*miR-17* and *-20* Expression Correlates with Biguanide Sensitivity in Human Lymphoma Cells {#sec2.5}
-------------------------------------------------------------------------------------------

Having defined the downstream effects of biguanides on the metabolism and viability of *miR-17∼92*-expressing *Myc*^***+***^ lymphoma cells, we expanded our analysis to test biguanide sensitivity in a panel of human lymphoma cell lines. Ten verified *MYC*^*+*^ lymphoma cell lines were used for this analysis: SU-DHL-4, OCI-Ly7, Jeko-1, Rec-1, Karpas 1718, OCI-Ly-1, OCI-Ly-2, OCI-Ly-3, OCI-Ly-8, and OCI-Ly-18. For each cell line, we measured levels of both the primary (*pri-miR*) and mature (*miR*) forms of *miR-17* and *miR-20* and determined the EC~50~ for cell viability to phenformin or IM156. From these data, we observed a negative correlation between the relative level of *miR-17* and -*20* expressed in cells and the dose of biguanide required to achieve EC~50~ ([Figures 6](#fig6){ref-type="fig"}A, 6B, and [S2](#mmc1){ref-type="supplementary-material"}; [Table S1](#mmc1){ref-type="supplementary-material"}), with cells displaying the highest *miR-17 and* -*20* expression showing the greatest sensitivity to biguanide treatment. Levels of *pri-miR-17* were a better predictor of biguanide sensitivity than mature *miR-17* ([Figures 6](#fig6){ref-type="fig"}A and 6B). IM156 was more potent than phenformin in inducing cell death in human lymphoma cells, similar to that observed in Eμ*-Myc*^*+*^ lymphoma cells. These data demonstrate *miR-17* expression as a biomarker for biguanide sensitivity.Figure 6*miR-17 and* -*20* Expression Correlates with Biguanide Sensitivity in Human Lymphoma Cells(A and B) EC~50~ for phenformin (Phen, left) and IM156 (right) correlated to the relative levels of pri-miR-17 (A) and mature miR-17 (B) transcripts for 10 human lymphoma cell lines. Linear regression (dotted line) is shown for both drugs with shaded 95% confidence interval.∗p \< 0.05, ∗∗p \< 0.01, and ∗∗∗p \< 0.001.

Discussion {#sec3}
==========

Myc is abnormally expressed in many human cancers; however, the development of small molecule Myc inhibitors has been a persistent challenge,[@bib37] prompting consideration of alternative approaches to *Myc* targeting. Here, we report that a downstream target of *Myc*-driven metabolism, *miR-17∼92*, while increasing bioenergetic capacity of tumor cells also increases sensitivity to apoptosis induced by biguanides. Using both classic (phenformin) and newly developed (IM156) biguanides, we demonstrated that human and mouse lymphoma cells with elevated *miR-17∼92* expression were highly sensitized to biguanide treatment. As single agents, both phenformin and IM156 were effective at extending the survival of mice bearing *miR-17∼92*-expressing lymphomas. In addition, we observed a statistical correlation between *miR-17* levels in human lymphoma cells and sensitivity to biguanide treatment. Our data provide rationale for the clinical investigation of *miR-17∼92* expression level as a potential biomarker for biguanide sensitivity in cancer.

Enhanced Myc activity leads to the overexpression of *miR-17∼92*, which in turn lowers LKB1 expression. This leads to enhanced tumor growth associated with increased glycolysis and oxidative phosphorylation, but it also reduces the capacity of lymphoma cells to activate the LKB1-AMPK system to overcome the energetic stress imposed by biguanides. These cells are then susceptible to apoptosis upon biguanide treatment, as both phenformin and IM156 inhibit oxidative phosphorylation, and the LKB1-AMPK system cannot be activated to respond to this inhibition. Another important function of LKB1-AMPK signaling is the surveillance of mitochondrial integrity.[@bib38] The potential impact of *miR-17∼92* on mitochondrial homeostasis and changes in response to biguanide treatment remains to be determined.

Our results address gaps in knowledge related to the mechanism by which LKB1 loss induces biguanide sensitivity. Previous work indicates that phenformin treatment increases reactive oxygen species (ROS) levels in cells with reduced LKB1 expression,[@bib8] leading to oxidative damage and preferential cell death of LKB1 null tumor cells. We show here that glucose- and glutamine-dependent fueling of the TCA cycle was inhibited in *miR-17∼92*-expressing lymphoma cells responding to biguanide treatment. This fueling is a key node for the production of reducing equivalents for ATP production and biosynthetic intermediates for growth (e.g., citrate, aspartate). Our data are consistent with observations that reducing mitochondrial aspartate production in tumor cells can impair cell viability, due in part to diminished purine and pyrimidine biosynthesis.[@bib39]^,^[@bib40] Reduced biosynthetic metabolism, combined with reduced mitochondrial NADH production and an inability to activate AMPK signaling, appear to sensitize *miR-17∼92*-expressing lymphoma cells to metabolic stress. Consistent with this, biguanide treatment, particularly IM156, slowed lymphoma cell growth *in vitro* and extended the lifespan of tumor-bearing mice.

There has been increased interest in the clinical use of biguanides for cancer therapy. Encouraging preclinical data[@bib17] have led to \>100 clinical trials of metformin for indications in oncology,[@bib21] but the results of randomized trials have been disappointing. The lack of clinical benefit of metformin in trials reported to date does not necessarily imply that biguanides as a class have no activity. Pharmacokinetic factors may account at least in part for the discrepancies between preclinical models and clinical trials with respect to the antineoplastic activity of metformin. The hydrophilic nature of metformin dictates that cellular uptake is dependent on OCT1 transporters before gaining access to mitochondria.[@bib31] This inherently limits the action of metformin to those cells expressing OCT1, which can vary between tumors.[@bib41] The biguanide phenformin displays greater bioavailability and antineoplastic activity than metformin,[@bib31]^,^[@bib41]^,^[@bib42] but its clinical use has been limited due to the risk of lactic acidosis, especially in patients with compromised renal or liver function.[@bib43] These results justify the investigation of novel biguanides with better pharmacokinetic and pharmacodynamic properties than metformin in neoplastic tissue as a strategy for OXPHOS inhibition for cancer treatment.

We identified IM156 from a library of ≥1,000 biguanides as a potential anticancer drug candidate.[@bib44] Our data indicate that IM156 is a more potent OXPHOS inhibitor than metformin or phenformin. IM156 may have advantages over metformin as it is a more potent, hydrophilic biguanide that we hypothesize is more bioavailable in neoplastic tissues. IM156 is presently being evaluated in a Phase I clinical trial (NCT 032 72256) in patients with advanced solid tumors and lymphoma. Our work here explored the use of IM156 as a monotherapy for cells with reduced LKB1-AMPK signaling, but combination therapy with other metabolic targets may increase efficacy with this agent. Recent reports have demonstrated synthetic lethality in tumor cells when metformin is combined with the pharmacological inhibition of monocarboxylate transporters (MCTs),[@bib45]^,^[@bib46] due in part to ATP depletion following the loss of NAD^+^ regeneration when lactate cannot be exported by MCT1 or MCT4. Inhibition of aspartate synthesis by the malate-aspartate shuttle enzyme *Got1* also synergizes with biguanides to enhance cancer cell death.[@bib40]

Our research adds to prior evidence[@bib8]^,^[@bib47] that clinical trials of biguanides or other OXPHOS inhibitors are likely to show clinical activity if evaluated in patients with cancers that are particularly sensitive to energetic stress, such as those with elevated expression of *MYC* or *miR-17∼92* and/or decreased function of LKB1. Although LKB1 inactivation is relatively common in NSCLC,[@bib7] it is not common among other malignancies. In contrast, *MYC* is among the most commonly dysregulated oncogenes in both hematologic malignancies and solid tumors. Because of the paucity of viable treatments targeting *MYC*-driven cancers, linking the downstream *MYC* target *miR-17∼92* to the inhibition of LKB1 may identify a cohort of patients without LKB1 mutations who are particularly sensitive to biguanide treatment, opening avenues for the treatment of these cancers.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit polyclonal anti-human/mouse beta-actin (1:2000 dilution)Cell SignalingCat \# 4967Rabbit polyclonal anti-human/mouse 4E-BP (1:1000 dilution)Cell SignalingCat \# 9452Rabbit polyclonal anti-human/mouse 4E-BP (phospho-T36/47) (1:1000 dilution)Cell SignalingCat \# 9459Rabbit polyclonal anti-human/mouse rS6 (pS235/236) (1:1000 dilution)Cell SignalingCat \# 2211Mouse monoclonal anti-human/mouse rS6 (54D2) (1:1000 dilution)Cell SignalingCat \# 2317Rabbit monoclonal anti-human/mouse Raptor (24C12) (1:1000 dilution)Cell SignalingCat \# 2280Rabbit polyclonal anti-human/mouse Raptor (pS792) (1:1000 dilution)Cell SignalingCat \# 2083Rabbit polyclonal anti-human/mouse AMPKα (1:1000 dilution)Cell SignalingCat \# 2532Rabbit monoclonal anti-human/mouse AMPKα (pT172) (40H9) (1:1000 dilution)Cell SignalingCat \# 2535Mouse monoclonal primary anti-human/mouse/rat LKB1 (Ley 37D/G6) (1:2500 dilution)Santa Cruz BiotechnologyCat \# sc-32245Rabbit polyclonal anti-human/mouse Caspase3 (1:1000 dilution)Cell SignalingCat \# 9662**Biological Samples***Bos taurus* (bovine) heartC. Humphries & SonsN/A**Chemicals, Peptides, and Recombinant Proteins**Metformin hydrochlorideToronto Research ChemicalsCat \# M258815phenforminToronto Research ChemicalsCat \# P296900sucraloseSigmaCat \# 69293-100G4-OHTSigmaCat \# H7904-5MGXF Base Medium Minimal DMEM without Phenol RedAgilentCat \# 103335-100IMDM GlutaMAXThermo FisherCat \# 3198-022Fetal bovine serumWisent-BioproductsCat \# 080-450Penicillin-streptomycinWisent-BioproductsCat \# 450-201-ELL-GlutamineBiochrom AGCat \# M11-0042-mercaptoethanolGIBCOCat \# 21985-023RPMIWisentCat \# 350-000puromycinBioShop CanadaCat \# PUR333.25butanolSigma-AldrichCat \# B7906-500MLhydrochloric acid, 6NFisher ScientificCat \#SA56-4sodium dicyanamideSigma-AldrichCat \# 178322-25GphenylamineSigma-AldrichCat \# 242284-500MLtrypan blueLifeTech (Biobar)Cat \# 15250-061Fixable Viability Dye eFluor 780eBioscienceCat \# 65-0865-14\[U-^13^C\]-glucoseCambridge IsotopesCat \# CLM-1396FCCPCaymanCat \# 15218OligomycinSigma-AldrichCat \# 1404-19-9RotenoneCaymanCat \# 13955Antimycin ASigma AldrichCat \# A8674Poly-D-lysine hydrobromideSigma AldrichCat \# P6407Lipofectamine 3000Thermo FisherCat \# L3000001TrizmaSigma AldrichCat \# T1503sucroseSigma AldrichCat \# S0389horse heart cytochrome *c*Sigma AldrichCat \# C2506NADHSigma AldrichCAS \# 606-68-6Malic enzymeJones and Hirst[@bib53]N/AFumaraseJones and Hirst[@bib53]N/Apotassium sulfate (KSO~4~)Sigma AldrichCat \# P0772magnesium sulfate (MgSO~4~)VWRCat \# 2312982sodium succinateSigma AldrichCat \# S2378NADP^+^Sigma AldrichCat \# N05853-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate (CHAPS)Santa Cruz BiotechnologyCat \# sc-29088Asoy bean asolectinAvanti Polar LiquidsCat \# 541601Gdecylubiquinone (DQ)Santa Cruz BiotechnologyCat \# sc-358659DMSOFisher BioreagentsCat \# BP231-100Glucose ≥ 99,5% D(+)RothCat \# HN06.1\[^13^C~1~\]-glutamineCambridge IsotopesCat \# CLM-3612-PK\[U-^13^C\]-glucoseCambridge IsotopesCat \# CLM-1396methanolVWRCAMX0475-1D-myristic acidSigma AldrichCat \# 366889-1Gmethoxyamine hydrochlorideSigma AldrichCat \# 226904-5GpyridineSigma AldrichCat \# 270970-100MLN-(*tert*-butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA)Sigma AldrichCat \# 394882-5MLCHAPS buffer (10 mM Tris-HCl, 1 mM MgCl2, 1 mM EGTA, 0.5 mM CHAPS, 10% glycerol, and 5 mM NaF)(Faubert et al., 2014)[@bib4]N/AAMPK lysis buffer, RIPA bufferCell SignalingCat \# 9806SQIAzol lysis reagentQIAGENCat \# 79306HBSSWisentCat \# 311-510-CL**Critical Commercial Assays**Seahorse XFe96 FluxPakAgilent TechnologiesCat \# 102416-100miRNeasy Mini kitQIAGENCat \# 217004miScript II RT kitQIAGENCat \# 218160SensiFAST SYBR Lo-Rox MixBiolineCat \# BIO-92005miScript primer assaysQIAGENCat \# 218300Dual-Glo Luciferase assay kitPromegaCat \# E2920**Experimental Models: Cell Lines**Eμ-*Myc* lymphoma cellsIzreig et al.[@bib30]N/AEμ-*Myc Cre-ERT2*^*+*^; *miR-17∼92*^*fl/fl*^ lymphoma cellsMu et al.[@bib32]N/ARaji lymphoma cellsIzreig et al.[@bib30]N/A293T, human embryonic kidney (HEK) cellsATCCCat \# CRL-3216*Ink4a*-null MEF feeder cellsIzreig et al.[@bib30]N/A**Experimental Models: Organisms/Strains**CD-1 nude mice, Crl:CD1-*Foxn1*^*nu*^Charles River LaboratoriesCat \# CR:086**Recombinant DNA**Stk11 shRNA (LMP backbone): 5′- AGGTCAAGATCCTCAAGAAGAA −3′Izreig et al.[@bib30]N/AYeast NDI1Wheaton et al.[@bib28]N/A**Software and Algorithms**FlowJo 9.9.5FlowJo LLC<https://www.flowjo.com>GraphPad Prism V6 or V7GraphPad Software<https://www.graphpad.com>El-MavenElucidata Inc<https://elucidatainc.github.io/ElMaven/>Bioenergetics Calculations SpreadsheetMookerjee et al.[@bib50]<https://russelljoneslab.vai.org/tools>Mass isotopomer distribution for TCA cycle intermediates was determined using a custom algorithm developed at McGill UniversityMcGuirk et al.[@bib54]N/A**Other (Mouse Diets)**Teklad global soy protein-free extruded rodent dietEnvigoCat \# 2020X

Resource Availability {#sec4.2}
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### Lead Contact {#sec4.2.1}

Additional information and request for resources and reagents should be directed to and will be made available by the Lead Contact, Russell G. Jones (<russell.jones@vai.org>).

### Materials Availability {#sec4.2.2}

All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement. The biguanide IM156 is the intellectual property of ImmunoMet Therapeutics. Requests for ImmunoMet Therapeutics reagents can be made through the Lead Contact.

### Data and Code Availability {#sec4.2.3}

All data associated with this study are available in the main text or the supplementary materials. A spreadsheet to assist in converting OCAR and ECAR Seahorse data into oxidative and glycolytic ATP production rates is available at <https://russelljoneslab.vai.org/tools>. This study did not generate any code.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

CD-1 nude mice were purchased from Charles River Laboratories (Wilmington, MA). All animals had *ad libitum* access to food and water and were maintained at 22--24°C on a 12-hour light/12-hour dark cycle with 5 mice per cage. Mice were bred and maintained under specific pathogen-free conditions at McGill University under approved protocols. For tumor xenograft assays, water bottles carrying 1.2% sucralose, 0.9 mg/mL phenformin +1.2% sucralose, or 0.8 mg/mL IM156 + 1.2% sucralose were provided for *ad libitum* consumption. Mice were observed daily for health status until clinical displays of disease, such as weight loss and poverty of movement, met IACUC criteria for euthanasia at which point mice were euthanized. Experiments were performed on female mice between 8 and 20 weeks of age.

### Cell lines {#sec4.3.2}

HEK293 cells were obtained from ATCC. Expression constructs for NDI1 were a generous gift of Dr. Navdeep Chandel.[@bib28] The generation of Eμ-*Myc Cre-ERT2*^*+*^; *miR-17∼92*^*fl/fl*^ lymphoma cells has been described previously.[@bib32] Deletion of *miR-17∼92* was achieved by culturing Eμ-*Myc Cre-ERT2*^*+*^;*miR-17∼92*^*fl/fl*^ cells with 250 nM 4-OHT for four days,[@bib32] followed by subcloning 4-OHT-treated cells to isolate cells deficient for *miR-17∼92*. Eμ-*Myc* cells were cultured on a layer of irradiated *Ink4a* null MEF feeder cells in DMEM and IMDM medium (50:50 mix) supplemented with 10% fetal bovine serum (FBS), 20000 U/mL penicillin, 7 mM streptomycin, 2 mM glutamine, and β-mercaptoethanol. Raji cells were cultured in RPMI medium supplemented with 10% FBS, 20000 U/mL penicillin, 7 mM streptomycin, and 2 mM glutamine. Cells were grown at 37°C in a humidified atmosphere supplemented with 5% (v/v) CO~2~. Retroviral-mediated gene transfer into lymphoma cells was conducted as previously described.[@bib30] Briefly, lymphoma cells were transduced via spin infection, followed by culture in 4 μg/mL puromycin for four days, and subsequent subcloning by limiting dilution. *miR-17∼92* constructs have been previously described.[@bib32] Knockdown of *Stk11* via shRNA (sequence: 5′- AGGTCAAGATCCTCAAGAAGAA −3′) has been described.[@bib30]

Method Details {#sec4.4}
--------------

### Synthesis of IM156 {#sec4.4.1}

IM156 was synthesized as previously reported.[@bib48] In brief, pyrrolidine was dissolved in butanol before concentrated hydrochloric acid was added and stirred for 30 min at 0°C. Sodium dicyanamide was then added and stirred for 24 h under reflux. After completion of the reaction was confirmed, the adduct---N1-pyrollidine cyanoguanidine---was purified. Next, phenylamine was dissolved in butanol before concentrated hydrochloric acid was added and stirred for 30 min at room temperature. The N1-pyrollidine cyanoguanidine prepared above was then added and stirred for 6 h under reflux. This mixture was concentrated under reduced pressure then dissolved in a 6 N hydrochloric acid/methanol solution before adding ethyl acetate. The precipitate---IM156A HCl---was filtered and dried under reduced pressure. IM156.HCl can be converted to free form by adding sodium hydroxide. The free form can be converted to the acetate salt form---IM156A---by adding acetic acid.

### Cell proliferation and viability assays {#sec4.4.2}

Cells were seeded at a density of 1 × 10^5^ cells/mL in 3.5 cm dishes, and cell counts determined via trypan blue exclusion using a TC20 Automated Cell Counter (Biorad). For viability measurements, cells were stained with Fixable Viability Dye eFluor 780 (eBioscience) and analyzed using a Gallios flow cytometer (Beckman Coulter, Fullerton, CA) and FlowJo software (Tree Star, Ashland, OR).

### Seahorse XF96 Respirometry and metabolic assays {#sec4.4.3}

Cellular oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were determined using an XF96 Extracellular Flux Analyzer (Seahorse Bioscience) using established protocols.[@bib49] In brief, lymphoma cells (7.5 × 10^4^ per well) were plated in poly-D-lysine-coated XF96 Seahorse plates in 140 μL of unbuffered DMEM containing 25 mM glucose and 2 mM glutamine, followed by centrifugation at 500xg for five minutes. XF assays consisted of sequential mix (3 min), pause (3 min), and measurement (5 min) cycles, allowing for determination of OCR and ECAR every 8 min. Following four baseline measurements, 20 μL of untreated media, phenformin, or IM156 were injected into respective wells, and OCR and ECAR tracked over time. We converted ECAR and OCR measurements into glycolytic and oxidative ATP production rates based on protocols developed by Mookerjee and Brand.[@bib50] This method allows us to directly compare the contribution of glycolysis and OXPHOS to ATP production while correcting for the contribution of glycolysis and TCA cycle metabolism to ECAR. Tools to complete this analysis are available for download at <https://russelljoneslab.vai.org/tools>.

HEK293 cells were transfected with vectors expressing empty vector (Ctrl) or yeast NADH dehydrogenase NDI1 using Lipofectamine 3000 according to manufacturer's instructions. Transfected HEK293 cells were seeded at a density of 30,000 cells/well in poly-D-Lysine-coated Seahorse plates. Oxygen consumption rates were recorded by using Seahorse XF96 bioanalyzer in the presence of serial dilution of IM156 as described above.

### Complex I and mitochondrial membrane kinetic measurements {#sec4.4.4}

Mitochondrial membranes[@bib51] and purified complex I[@bib52] were prepared from *Bos taurus* (bovine) heart. All assays were performed at 32°C in a SpectraMax 96-well plate reader and maximal rates determined by linear regression. NADH:O~2~ oxidoreduction by membranes was measured using 5 μg/mL membranes in 10 mM Tris-HCl (pH 7.4), 250 mM sucrose, and 0.15 μM horse heart cytochrome *c* (Sigma-Aldrich Ltd.) with 200 μM NADH and monitored using ε~340--380(NADH)~ = 4.81 mM^−1^cm^−1^. Succinate:O~2~ oxidoreduction was measured using a coupled enzyme assay using 300 ug/mL Malic enzyme and 60 ug/mL Fumarase both prepared as described.[@bib53] Activity was measured in the same buffer as above with the addition of 1 mM KSO~4~ and 2 mM MgSO~4~ using 5 μg/mL membranes with 5 mM succinate and 2 mM NADP^+^. This was monitored using ε~340--380(NADPH)~ = 4.81 mM^−1^ cm^−1^ as described previously.[@bib53] NADH:decylubiquinone oxidoreduction by purified complex I was measured using 0.5 μg/mL complex I in 20 mM Tris-HCl (pH 7.2), 0.15% 3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate (CHAPS, Merck Chemicals Ltd), and 0.15% soy bean asolectin (Avanti Polar Lipids), with 200 μM decylubiquinone (DQ, Santa Cruz Biotechnology) and 200 μM NADH, and monitored as above. IM156A was added from a DMSO stock and control experiments included DMSO.

### GC-MS analysis of ^13^C-labeled metabolites {#sec4.4.5}

Cellular metabolites were extracted and analyzed by GC-MS using previously described protocols.[@bib4]^,^[@bib30] Eμ-*Myc* cells (3-5 × 10^6^ per 3.5 cm dish) were incubated for 2 hours in untreated, 100 μM phenformin, or 10 μL IM156 medium containing 10% dialyzed FBS and U-\[^13^C\]-glucose or U-\[^13^C\]-glutamine (Cambridge Isotope Laboratories). Cells were washed twice with normal saline, then lysed in ice-cold 80% methanol and sonicated. For GC-MS analysis, D-myristic acid (750 ng/sample) was added to metabolite extracts as an internal standard prior to drying samples by vacuum centrifugation with sample temperature controlled at −4°C (LabConco). Dried extracts were dissolved in 30 μL methoxyamine hydrochloride (10 mg/ml) in pyridine and derivatized as tert-butyldimethylsilyl (TBDMS) esters using 70 μL N-(*tert*-butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA). An Agilent 5975C GC-MS equipped with a DB-5MS+DG (30 m x 250 μm x 0.25 μm) capillary column (Agilent J&W, Santa Clara, CA, USA) was used for all GC-MS experiments, and data collected by electron impact set at 70 eV. A total of 1 μL of derivatized sample was injected per run in splitless mode with inlet temperature set to 280°C, using helium as a carrier gas with a flow rate of 1.5512 mL/min (rate at which D27-myristic acid elutes at 17.94 min). The quadrupole was set at 150°C and the GC/MS interface at 285°C. The oven program for all metabolite analyses started at 60°C held for 1 min, then increasing at a rate of 10°C/min until 320°C. Bake-out was at 320°C for 10 min. Sample data were acquired in scan mode (1--600 m/z). Mass isotopomer distribution for TCA cycle intermediates was determined using a custom algorithm developed at McGill University[@bib54]. After correction for natural ^13^C abundances, a comparison was made between non-labeled (^12^C) and ^13^C-labeled abundances for each metabolite. Metabolite abundance was expressed relative to the internal standard (D-myristic acid) and normalized to cell number.

### Immunoblotting and Quantitative Real-Time PCR {#sec4.4.6}

Lymphoma cell lines were subjected to SDS-PAGE and immunoblotting using CHAPS and AMPK lysis buffers as previously described.[@bib55] Primary antibodies against β-actin, 4EBP (total, phospho-T36/47), rS6 (total and p S235/236), Raptor (total and pS792), AMPKα (total and phospho-T172), and Caspase-3 were obtained from Cell Signaling Technology (Danvers, MA). Primary antibody against LKB1 (Ley 37D/G6) was obtained from Santa Cruz Biotechnology (Dallas, TX, USA). HRP-conjugated secondary antibodies from Cell Signaling Technologies were used to detect primary antibodies, and immobilized proteins detected by chemiluminescence using Pearce ECL Substrate (ThermoFisher Scientific). *For* qPCR quantification of mature miRNAs, Qiazol was used to isolate RNA, miRNEasy Mini kit was used to purify miRNAs and total mRNA, and cDNA was synthesized using the miScript II RT kit (QIAGEN). Quantitative PCR was performed using the SensiFAST SYBR Hi-ROX kit (Bioline) and an AriaMX Real Time PCR system (Agilent Technologies). miScript primer assays (QIAGEN) were used to detect mature miRNAs of the *miR-17∼92* cluster, with miRNA expression normalized relative to U6 RNA levels.

### Tumor xenograft assays {#sec4.4.7}

Lymphoma cells were resuspended in HBSS at a concentration of 5 × 10^6^ cells/mL, and 10^6^ cells/200 μL were injected intravenously into CD-1 nude mice (Charles River). Water bottles carrying 1.2% sucralose, 0.9 mg/mL phenformin +1.2% sucralose, or 0.8 mg/mL IM156 + 1.2% sucralose were provided for ad lib consumption.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistics were determined using paired Student's t test, ANOVA, or Log-rank (Mantel--Cox) using Prism software (GraphPad) unless otherwise stated. Data are calculated as the mean ± SEM for biological triplicates and the mean ± SD for technical replicates unless otherwise stated. Statistical significance is represented in figures by: ∗, p \< *0.05*; ∗∗, p \< *0.01*; ∗∗∗, p \< *0.001*.

Additional Resources {#sec4.6}
--------------------

Spreadsheet (to assist in converting OCAR and ECAR Seahorse data into glycolytic and oxidative ATP production rates based on protocols developed by Mookerjee and Brand[@bib50]): <https://russelljoneslab.vai.org/tools>.
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